Corcept Therapeutics Inc (NASDAQ:CORT) shares are under heavy pressure Thursday morning after the U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey district court decision finding no infringement of two Korlym-related patents by Teva Pharmaceutical Industries Ltd’s (NASDAQ:TEVA) proposed generic.
Appeals Court Upholds Ruling Against Corcept
Corcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole.
The appeals court agreed with the lower court that there was no proof doctors had used, or were likely to use, those specific regimens, especially given safety concerns and the availability of newer alternatives like osilodrostat.
Generic Threat Clouds Korlym Outlook For CORT
The ruling removes a major legal barrier for Teva's Korlym generic, increasing the risk of earlier-than-hoped competition to Corcept's flagship franchise once regulatory requirements are satisfied.
With the court concluding that Teva's label can be followed without practicing Corcept's claimed methods, the company loses a key patent shield around Korlym's dosing with CYP3A inhibitors.
https://finviz.com/news/316211/corcept-therapeutics-stock-plunges-as-court-clears-teva-generic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.